<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.1.0//EN//XML?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName art510.dtd?>
  <?SourceDTD.Version 5.1.0?>
  <?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <?origin publisher?>
  <?FILEmeta_TIBTEC846 xml ?>
  <?FILEmain xml ?>
  <?FILEgr1 jpg ?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Trends Biotechnol</journal-id>
      <journal-title-group>
        <journal-title>Trends in Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0167-7799</issn>
      <issn pub-type="epub">1879-3096</issn>
      <publisher>
        <publisher-name>Elsevier Science Publishers</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3016495</article-id>
      <article-id pub-id-type="pmid">20971518</article-id>
      <article-id pub-id-type="publisher-id">TIBTEC846</article-id>
      <article-id pub-id-type="doi">10.1016/j.tibtech.2010.09.007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Identifying and validating biomarkers for Alzheimer's disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Humpel</surname>
            <given-names>Christian</given-names>
          </name>
          <email>christian.humpel@i-med.ac.at</email>
        </contrib>
      </contrib-group>
      <aff>Laboratory of Psychiatry and Experimental Alzheimer's Research, Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria</aff>
      <pub-date pub-type="pmc-release">
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <volume>29</volume>
      <issue>1</issue>
      <fpage>26</fpage>
      <lpage>32</lpage>
      <permissions>
        <copyright-statement>&#xC2;&#xA9; 2011 Elsevier Ltd.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The identification and validation of biomarkers for diagnosing Alzheimer's disease (AD) and other forms of dementia are increasingly important. To date, ELISA measurement of &#x3B2;-amyloid(1&#x2013;42), total tau and phospho-tau-181 in cerebrospinal fluid (CSF) is the most advanced and accepted method to diagnose probable AD with high specificity and sensitivity. However, it is a great challenge to search for novel biomarkers in CSF and blood by using modern potent methods, such as microarrays and mass spectrometry, and to optimize the handling of samples (e.g. collection, transport, processing, and storage), as well as the interpretation using bioinformatics. It seems likely that only a combined analysis of several biomarkers will define a patient-specific signature to diagnose AD in the future.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec0005">
      <title>Diagnosing Alzheimer's disease (AD) and other forms of dementia</title>
      <p>AD is a severe neurodegenerative disorder of the brain that is characterized by loss of memory and cognitive decline. The majority of AD cases are sporadic (risk age &gt;60 years), and &lt;2.5% have a genetic disposition. It is estimated that in 2050, approximately 80 million people will suffer from AD worldwide. Thus, it is a great challenge to establish reliable surrogate markers to diagnose and monitor disease progression. Definitive diagnosis requires both clinical assessment of the disease and post-mortem verification of the AD pathology (plaques and tangles). A probable diagnosis of AD can be established with a confidence of &gt;90%, based on clinical criteria, including medical history, physical examination, laboratory tests, neuroimaging and neuropsychological evaluation. Accurate, early diagnosis of AD is still difficult because early symptoms of the disease are shared by a variety of disorders, which reflects common neuropathological features. An ideal biomarker would distinguish AD from other types of dementia, such as mild cognitive impairment (MCI), or mixed forms of dementia, such as vascular dementia (VaD), frontotemporal lobe dementia (FTLD), or Lewy body dementia (LBD). This is important because treatment for these diseases might differ.</p>
    </sec>
    <sec id="sec0010">
      <title>What is a biomarker?</title>
      <p>A biological marker, or biomarker <xref rid="bib0005 bib0010 bib0015 bib0020 bib0025" ref-type="bibr">[1&#x2013;5]</xref>, is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. A biomarker can serve as an indicator of health (i.e. biomarker of ageing) and disease. The sensitivity, specificity and ease-of-use are the most important factors that ultimately define the diagnostic utility of a biomarker. Some biomarkers are more reasonably viewed as risk factors rather than true disease markers. In order for a diagnostic biomarker to be useful, certain criteria must be met (<xref rid="tb0005" ref-type="boxed-text">Box 1</xref>) <xref rid="bib0030 bib0035 bib0040 bib0045" ref-type="bibr">[6&#x2013;9]</xref>.</p>
    </sec>
    <sec id="sec0015">
      <title>Biomarkers for AD in cerebrospinal fluid (CSF)</title>
      <p>Three biomarkers have been well-established and validated internationally to diagnose AD in CSF with ELISAs: &#x3B2;-amyloid(1&#x2013;42) [A&#x3B2;(1&#x2013;42)], total tau and phospho-tau-181. It is now the consensus that only the combination of these three CSF biomarkers significantly increases the diagnostic validity for sporadic AD, which yields a combined sensitivity of &gt;95% and a specificity of &gt;85% <xref rid="bib0050 bib0055 bib0060 bib0065" ref-type="bibr">[10&#x2013;13]</xref>.</p>
      <sec id="sec0020">
        <title>A&#x3B2;(1&#x2013;42)</title>
        <p>AD is characterized by extracellular A&#x3B2; plaque depositions. A&#x3B2; is cleaved from the large amyloid-precusor protein (APP) by secretases, and processing of amyloidogenic pathways produces a 42-amino-acid peptide [A&#x3B2;(1&#x2013;42)] that can aggregate in the brain under certain conditions (e.g. acidosis, metals). Analysis of CSF A&#x3B2;(1&#x2013;42) shows a highly significant reduction in AD patients compared to controls, with a cut-off of &lt;500 pg/ml (<xref rid="tbl0005" ref-type="table">Table 1</xref>). It has been suggested that reduced levels of A&#x3B2;(1&#x2013;42) in the CSF are caused by reduced clearance of A&#x3B2; from the brain to the blood/CSF, as well as enhanced aggregation and plaque deposition in the brain. Changes in CSF A&#x3B2; levels differ based on the disease (<xref rid="tbl0010" ref-type="table">Table 2</xref>) <xref rid="bib0070 bib0075 bib0080" ref-type="bibr">[14&#x2013;16]</xref>. For example, decreased A&#x3B2;(1&#x2013;38) levels correlate with FTLD, and A&#x3B2;(1&#x2013;37) levels with LBD <xref rid="bib0020" ref-type="bibr">[4]</xref>. CSF levels of shorter A&#x3B2;(1&#x2013;40) forms are unchanged or increased in AD. It has therefore been suggested that the A&#x3B2;42/A&#x3B2;40 ratio can improve AD diagnosis, but others have not found such changes <xref rid="bib0085 bib0090" ref-type="bibr">[17,18]</xref>. Novel detection methods allow measurement of A&#x3B2; oligomers, which might improve the diagnostic specificity. As an example, surface-enhanced laser desorption/ionization-time-of-flight-mass spectrometry (SELDI-TOF-MS) (<xref rid="tbl0015" ref-type="table">Table 3</xref>) has emerged as an ideal method for the simultaneous detection and quantitation of a variety of A&#x3B2; peptide cleavage products <xref rid="bib0095" ref-type="bibr">[19]</xref>.</p>
      </sec>
      <sec id="sec0025">
        <title>Total tau</title>
        <p>The second hallmark of AD are intraneuronal inclusions of the microtubule-associated protein tau. In healthy controls, levels of total tau in the CSF increase with age <xref rid="bib0100" ref-type="bibr">[20]</xref>: &lt;300 pg/ml (21&#x2013;50 years), &lt;450 pg/ml (51&#x2013;70 years), and &lt;500&#xA0;pg/ml (&gt;70 years). Total tau levels are significantly enhanced in AD patients as compared with age-matched control subjects with a cut off of &gt;600 pg/ml (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Total tau levels are dramatically enhanced in Creutzfeldt&#x2013;Jacob disease (CJD) (&gt;3000 pg/ml). Tau levels might also be a prognostic marker with a good predictive validity for conversion from MCI to AD, because high CSF tau level has been found in 90% of MCI cases that later progressed to AD, but not in cases with stable MCI <xref rid="bib0050" ref-type="bibr">[10]</xref>. Observed changes in CSF total tau level for different diseases are shown in <xref rid="tbl0010" ref-type="table">Table 2</xref> <xref rid="bib0070" ref-type="bibr">[14]</xref>.</p>
      </sec>
      <sec id="sec0030">
        <title>Phosphorylated tau</title>
        <p>Tau is markedly hyperphoshorylated (39 possible sites) in AD, which results in a lack of function and axonal transport dysfunction. The detection of tau phosphorylated at position 181 is significantly enhanced in AD compared to controls <xref rid="bib0105" ref-type="bibr">[21]</xref>, with a cut-off of &gt;60 pg/ml (<xref rid="tbl0005" ref-type="table">Table 1</xref>). The changes of CSF phospho-tau-181 levels in different diseases are given in <xref rid="tbl0010" ref-type="table">Table 2</xref> <xref rid="bib0070" ref-type="bibr">[14]</xref>. The analysis of other phosphorylated forms of tau (phospho-tau-199, -231, -235, -396 and -404) might offer significant improvements towards early diagnosis of AD <xref rid="bib0055" ref-type="bibr">[11]</xref>. Phospho-tau-231 and phospho-tau-181 can be used to distinguish AD from controls and FTLD, LBD, VaD and major depression <xref rid="bib0020 bib0105" ref-type="bibr">[4,21]</xref>. Furthermore, the concentration of phospho-tau-231 has shown longitudinal decline from mild to moderate AD <xref rid="bib0105" ref-type="bibr">[21]</xref>. It is a high priority to develop specific and sensitive ELISAs for other site-specific phosphorylated tau isoforms to improve the diagnostic repertoire for AD.</p>
      </sec>
      <sec id="sec0035">
        <title>Other CSF biomarkers</title>
        <p>Despite strong efforts to characterize other potential biomarkers in CSF, several biomarkers have been tested in CSF that have displayed changes between AD and controls <xref rid="bib0020 bib0110 bib0115" ref-type="bibr">[4,22,23]</xref>. However, no other single biomarker has been validated to date for routine diagnosis, because the changes are very heterogeneous and low, and data have differed between laboratories. Cognitive decline is highly correlated with loss of the neurotransmitter acetylcholine in the cortex or the hippocampus. Degeneration of cholinergic neurons can be prevented by application of nerve growth factor (NGF), which has been found to be reproducibly increased in CSF of AD patients <xref rid="bib0110 bib0115 bib0120" ref-type="bibr">[22&#x2013;24]</xref>; however, such low changes are not yet useful for establishing NGF as a biomarker. The use of mass spectrometry (MS) methods or different microarrays (<xref rid="tbl0015" ref-type="table">Table 3</xref>) might rapidly increase the knowledge on disease-related changes to uncover novel biomarkers in CSF of AD patients.</p>
      </sec>
    </sec>
    <sec id="sec0040">
      <title>Biomarkers in blood</title>
      <p>The routine diagnosis of AD and mixed forms of dementia from CSF has several drawbacks: lumbar puncture and collection of CSF is an invasive treatment with potential side effects, and screening of patients is often difficult and follow-up analysis of the same patient over several years is problematic. Thus, there is a clear need to search for biomarkers in other body fluids (<xref rid="tb0010" ref-type="boxed-text">Box 2</xref>) to diagnose AD <xref rid="bib0065" ref-type="bibr">[13]</xref>. Although saliva or urine can be easily collected, blood analysis is the gold standard (<xref rid="tb0010" ref-type="boxed-text">Box 2</xref>); yet, it is still unknown how the concentration of analytes in the blood directly correlates with pathological changes in the brain, especially in AD. The search for blood biomarkers that correlate with AD should therefore begin with accepted CSF markers, such as A&#x3B2; and tau-related biomarkers, and further include factors involved in inflammation, protein aging and cell death, and cerebrovascular dysfunctions.</p>
      <sec id="sec0045">
        <title>A&#x3B2;-related proteins</title>
        <p>Blood plasma levels of A&#x3B2; are increased in familial AD and Down syndrome, but results are inconsistent with sporadic AD <xref rid="bib0020" ref-type="bibr">[4]</xref>. Studies have shown that plasma A&#x3B2;(1&#x2013;42) and A&#x3B2;(1&#x2013;40) levels can be elevated, reduced or even unchanged in AD versus control patients <xref rid="bib0020 bib0070" ref-type="bibr">[4,14]</xref>. A significant increase in A&#x3B2;(1&#x2013;42) plasma levels has been seen in women with MCI, but not in men, as compared with cognitively normal, age-matched subjects <xref rid="bib0125" ref-type="bibr">[25]</xref>. Recent longitudinal studies have shown that high plasma A&#x3B2;(1&#x2013;42) levels are a risk factor for developing AD; however, there is agreement that this factor is not sensitive and specific for early diagnosis <xref rid="bib0130" ref-type="bibr">[26]</xref>. A decrease of serum A&#x3B2;(1&#x2013;42) autoantibodies has been found in AD <xref rid="bib0135" ref-type="bibr">[27]</xref>, yet no correlation between CSF and plasma A&#x3B2; levels has been found. Antigen-spotted microarrays could help identify and validate AD-selective biomarker autoantibodies in blood and CSF. Such a rapid assay has been developed, which measures the difference between dissociated sera and the corresponding non-dissociated sera <xref rid="bib0140" ref-type="bibr">[28]</xref>.</p>
        <p>There are several reasons why plasma levels of A&#x3B2;(1&#x2013;42) are unstable: (i) A&#x3B2; expression is influenced by medications <xref rid="bib0145" ref-type="bibr">[29]</xref>; (ii) A&#x3B2; binds to other proteins and thus becomes trapped; (iii) A&#x3B2; levels in blood fluctuate over time and among individuals, and might differ in mild, early and late AD; and (iv) blood platelets contain high amounts of A&#x3B2;, which directly affects plasma levels. Platelets express APP and the secretase machinery, and mainly process A&#x3B2;(1&#x2013;40), which plays a role in platelet aggregation. In platelets of AD patients, three subtypes of APP (106, 110 and 130 kDa) have been found <xref rid="bib0150 bib0155" ref-type="bibr">[30,31]</xref>. AD patients show enhanced processing of the 130-kDa APP subtype, which results in a mean APP form ratio &#x2013; [130 kDa subtype]/[(106 kDa subtype) + (110 kDa subtype)] &#x2013; of 0.35&#xB1;0.18, whereas controls have a mean ratio of &gt;0.83. A cut-off level of &gt;0.6 results in a sensitivity of 83% and a specificity of 71% when diagnosing AD <xref rid="bib0150 bib0155" ref-type="bibr">[30,31]</xref>.</p>
        <p>Autophagic degradation of intracellular components via the lysosomal pathway is abnormal in AD. Macrophages and monocytes of AD patients are generally poorly phagocytic for A&#x3B2;, whereas cells of control patients robustly internalize A&#x3B2; <xref rid="bib0160" ref-type="bibr">[32]</xref>. Phagocytosis of A&#x3B2; can be tested using <italic>in vitro</italic> differentiated monocytes/macrophages exposed to fluorescent A&#x3B2; <xref rid="bib0160" ref-type="bibr">[32]</xref>. Monocytes can be detected by immunofluorescent staining with anti-CD68 and visualized in flow cytometric tests (e.g. fluorescence-activated cell sorting) or by immunohistochemistry <xref rid="bib0160" ref-type="bibr">[32]</xref>.</p>
      </sec>
      <sec id="sec0050">
        <title>Enzymes related to tau pathology</title>
        <p>Tau is a brain-specific protein, and altered function of protein kinases and phosphatases has been implicated in tau pathology <xref rid="bib0105" ref-type="bibr">[21]</xref>. A number of kinases contribute to tau hyperphosphorylation, including glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5, and microtubule affinity-regulating kinase; conversely, protein phosphatase 2A dephosphorylates tau. It has been reported that GSK-3 is significantly increased in white blood cells in AD and MCI patients, as compared with healthy subjects <xref rid="bib0165" ref-type="bibr">[33]</xref>. This correlation notwithstanding, reduced GSK-3 levels in peripheral-blood mononuclear cells have also been noted in AD patients <xref rid="bib0170" ref-type="bibr">[34]</xref>, which indicates high variability. Protein kinase C (PKC) appears to be altered in fibroblasts, lymphocytes, and red blood cells of AD patients <xref rid="bib0175" ref-type="bibr">[35]</xref>, which supports the view that PKC conformation in peripheral cells could be an early predictive marker for AD. At present, tau-related biomarkers in the periphery do not seem to be useful for AD diagnosis.</p>
      </sec>
      <sec id="sec0055">
        <title>Inflammatory markers</title>
        <p>In the brain of an AD patient, neuroinflammatory processes occur, including activation of microglia and expression of proinflammatory cytokines, which probably contribute to neuronal cell death. A recent promising study has shown that the combination of 18 selected biomarkers (chemokines, cytokines, growth factors and binding proteins) in plasma might allow the diagnosis of AD <xref rid="bib0180" ref-type="bibr">[36]</xref> and MCI with nearly 90% accuracy. These 18 biomarkers have been selected from 120 signalling proteins by sandwich ELISAs (<xref rid="tbl0015" ref-type="table">Table 3</xref>). Recently, 16 of these 18 biomarkers have been tested using a similar Multiplex Searchlight ELISA system (Aushon: <ext-link ext-link-type="uri" xlink:href="http://www.aushon.com/">www.aushon.com</ext-link>) (<xref rid="tbl0015" ref-type="table">Table 3</xref>), but similar changes could not be confirmed, and furthermore, a lower sensitivity/specificity of 60% was demonstrated <xref rid="bib0185" ref-type="bibr">[37]</xref>. Similarly, the use of Luminex-based technology (<xref rid="tbl0015" ref-type="table">Table 3</xref>) yielded a diagnostic accuracy of only 70% <xref rid="bib0190" ref-type="bibr">[38]</xref>. The Luminex method differs from conventional ELISAs in the way that the capture antibody is attached to 5.6-&#x3BC;m polystyrene beads, which are internally dyed with fluorophores of different intensities, and can be detected using dual laser systems for classification and quantification.</p>
      </sec>
      <sec id="sec0060">
        <title>Other disease-related markers</title>
        <p>Failure of the ubiquitin&#x2013;proteasome pathway function has been linked to A&#x3B2; toxicity, and indeed ubiquitin levels are elevated in AD <xref rid="bib0195" ref-type="bibr">[39]</xref>. It is well known that ubiquitin levels are increased several-fold in the cerebral cortex and CSF of patients with AD. This increase strongly correlates with the degree of neurofibrillary changes in the tissue <xref rid="bib0200 bib0205" ref-type="bibr">[40,41]</xref>. In CD45<sup>+</sup> T lymphocytes, the ubiquitin&#x2013;proteasome pathway has been found to be reduced during ageing <xref rid="bib0200" ref-type="bibr">[40]</xref>. We have recently shown that in peripheral blood mononuclear cells, the enzymes for proteasomal activity (conjugating and activating enzymes E1 and E2) are changed <xref rid="bib0210" ref-type="bibr">[42]</xref>.</p>
        <p>Cellular senescence is a stress response phenomenon that results in functional changes, such as telomere shortening <xref rid="bib0215" ref-type="bibr">[43]</xref>. In peripheral blood cells of AD and VaD patients, shorter telomeres than those in age-matched controls have been discovered <xref rid="bib0220 bib0225 bib0230" ref-type="bibr">[44&#x2013;46]</xref>. Recently, it has been reported that fibroblasts from sporadic AD patients specifically express an anomalous and detectable conformational state of the senescence marker p53 (mutant-like p53) that allows for differentiation of AD subjects <xref rid="bib0235" ref-type="bibr">[47]</xref>. Peripheral blood cells of AD patients are also more sensitive to apoptosis <xref rid="bib0240 bib0245 bib0250" ref-type="bibr">[48&#x2013;50]</xref>. Increased apoptosis has been noted in CD4<sup>+</sup> T cells and natural killer cells of AD patients, accompanied by enhanced expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), the antioxidant enzyme superoxide dismutase 1 (SOD1), and different subtypes of caspases <xref rid="bib0255 bib0260" ref-type="bibr">[51,52]</xref>.</p>
        <p>In AD, damage of the cerebrovascular system, including the blood&#x2013;brain barrier and neurovascular unit, results in a loss of energy supply to the brain, accompanied by silent strokes; thus, measurement of biomarkers associated with cerebrovascular damage could provide sensitive instruments for the diagnosis of AD. It is well-established that high concentrations of C-reactive protein (CRP) are predictive of cognitive decline and dementia <xref rid="bib0265" ref-type="bibr">[53]</xref>. Furthermore, increased plasma homocysteine in combination with decreased folate and vitamin B12 are biomarkers for VaD, and might discriminate between AD and controls <xref rid="bib0270" ref-type="bibr">[54]</xref>. The analysis of vasodilators or vasoconstrictors (e.g. pro-adrenomedullin, pro-atrial natriuretic peptide, C-terminal endothelin 1 precursor fragment) or cell adhesion molecules [vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, ICAM-3, and P-selectin] might lead to improved diagnosis of AD <xref rid="bib0275" ref-type="bibr">[55]</xref>. Increased plasma levels of VCAM-1 and ICAM-1 have been observed in AD patients <xref rid="bib0275 bib0280" ref-type="bibr">[55,56]</xref>.</p>
      </sec>
    </sec>
    <sec id="sec0065">
      <title>Searching for patient-specific, multi-biomarker profile signatures</title>
      <p>The principal goal is to discover biomarkers, with the ultimate objective of identifying differentially expressed proteins between diseased and healthy controls. Novel and fast high-throughput systems dramatically enhance the analysis of thousands of proteins and genes (<xref rid="tbl0015" ref-type="table">Table 3</xref>) with very low volumes. It is becoming clear that the consideration of a single biomarker might not be potent enough to improve diagnostic specificity. Thus, it is essential to develop methods to measure several biomarkers together in a single well or on a biochip to create an accurate prognostic profile.</p>
      <p>DNA and RNA microarrays have led to the identification of multiple genes that appear in early stages of AD <xref rid="bib0025" ref-type="bibr">[5]</xref>; however, DNA/RNA microarrays or transcriptomics (<xref rid="tbl0015" ref-type="table">Table 3</xref>) alone probably provide only a limited view of the biological process. The combination of genomics and proteomics has rapidly gained interest, and such interdisciplinary research will markedly further biomarker discovery <xref rid="bib0285" ref-type="bibr">[57]</xref>. Thus, research needs to develop simple, inexpensive and rapid tools to measure several biomarkers at the same time. As an example, a combination of the following biomarkers on a single Multiplex Sandwich ELISA Microarray is a possibility: five-plex of macrophage inflammatory proteins-1&#x3B4; and -4 (MIP1&#x3B4; and MIP4), regulated upon activation normal T-cell (RANTES) <xref rid="bib0115" ref-type="bibr">[23]</xref>, tumor necrosis factor-alpha (TNF&#x3B1;) <xref rid="bib0185" ref-type="bibr">[37]</xref> and midregional pro-atrial natriuretic peptide (MR-proANP) <xref rid="bib0275" ref-type="bibr">[55]</xref> in plasma; a three-plex of ICAM-3, P-selectin and CD14 in monocyte extracts <xref rid="bib0280" ref-type="bibr">[56]</xref>; and a novel four-plex ELISA of selective APP 130-, 110- and 106-kDa proteins, including actin as a control from platelet extracts <xref rid="bib0155" ref-type="bibr">[31]</xref>. A combination of such a 12-plex array could have the potential to improve AD diagnosis from blood. The development of a patient-specific chip array could allow us to define specific, multi-biomarker profile signatures, which could even act as a prognosticator for AD.</p>
    </sec>
    <sec id="sec0070">
      <title>Future challenges and criteria for a good diagnostic assay</title>
      <p>Routine analysis of CSF samples (<xref rid="fig0005" ref-type="fig">Figure 1</xref>) is well-established worldwide; however, a common consensus <xref rid="bib0290" ref-type="bibr">[58]</xref> on several issues is still missing, and thus the interpretation and support of clinical diagnosis is still not unique. It is essential to define routine procedures for: (i) collection, transport, processing and storage of samples; (ii) analysis; and (iii) interpretation (diagnosis) and cut-off values.</p>
      <sec id="sec0075">
        <title>Handling of samples (collection, transport, processing and storage)</title>
        <p>It is crucially important to search not only for the biomarkers themselves, but also for biomarkers that are stable. Often, samples are collected by medical doctors outside hospitals and without a laboratory. They do not have the time to process or capability to freeze samples. Thus, it is highly desirable to identify biomarkers with long half-lives. RNAs are very unstable; therefore, these criteria largely exclude the use of RNA chips, unless RNA stabilizers are accessible. It also needs to be considered that several other parameters can influence the stability of a protein, such as repeated freeze/thaw cycles or long-term storage at room temperature. Even measurements of proteins in serum or plasma with or without EDTA, heparin, or citrate can produce variable results for the same biomarker. Worldwide multicenter studies are necessary to compare the diagnostic accuracy in different laboratories <xref rid="bib0295" ref-type="bibr">[59]</xref>.</p>
      </sec>
      <sec id="sec0080">
        <title>Analysis</title>
        <p>Analytical methods are often limited by cost. Commercial ELISAs (e.g. Innogenetics: <ext-link ext-link-type="uri" xlink:href="http://www.innogenetics.be/">www.innogenetics.be</ext-link>) for A&#x3B2;, tau and phospho-tau-181 are very expensive. We have calculated that a 96-well plate ELISA costs approximately &#x20AC;900, and three kits are typically needed for quantifying A&#x3B2;, total tau and phospho-tau-181. Analysis is performed in duplicate, and includes a standard curve. In this situation, the estimated cost is approximately &#x20AC;68 per patient, excluding personnel and laboratory expendables. Cheaper diagnostic methods that cost around &#x20AC;10 per patient are warranted. Towards this goal, it is necessary to develop a multiplexed ELISA system to measure all three biomarkers concurrently in a single well. The INNO-BIA AlzBio3 assay (Innogenetics) already allows simultaneous quantification of all three biomarkers using xMAP Luminex technology <xref rid="bib0300" ref-type="bibr">[60]</xref>.</p>
        <p>Another limitation is the analysis of lowly and highly expressed proteins in the same well. If we want to measure low-level proteins, then a dilution of 1:2 in the assay might be required; however, a high-level protein cannot be quantified at such a low dilution in the same well, because it reaches saturation. Therein lies the need for two separate assays, which increases the cost associated with diagnosis.</p>
      </sec>
      <sec id="sec0085">
        <title>Interpretation and cut-off values</title>
        <p>Finally, it is important to provide good interpretation of the data to support clinical diagnosis. In our experience, a medical doctor without a background in laboratory experimentation and analysis cannot interpret raw data. Thus, standardized testing and international cut-off values will be important.</p>
      </sec>
      <sec id="sec0090">
        <title>Validating novel biomarkers in AD diagnosis</title>
        <p>In the scientific search for biomarkers (<xref rid="fig0005" ref-type="fig">Figure 1</xref>), several additional criteria must be met and standardized: (i) healthy controls; (ii) clinical diagnosis and verification; and (iii) publication and validation by multicenter studies. First, it is important to collect healthy controls who are age-matched and have a similar lifestyle, sex and education. This is extremely difficult to achieve, and might explain the high variety in the data. The &#x2018;nun-study&#x2019; <xref rid="bib0305" ref-type="bibr">[61]</xref> has tried to overcome this problem by analyzing a well-defined cohort of people.</p>
        <p>Second, in the search for a biomarker, it is important to have a perfect clinical diagnosis. A medical doctor must collect all criteria for enabling a correct diagnosis (including anamnesis, family history, general blood markers, neuropsychology, and neuroimaging, excluding other diseases). Secure diagnosis of AD can only be defined by postmortem brain analysis. It is worth noting that, to date, CSF diagnosis only supports the clinical (not postmortem) diagnosis.</p>
        <p>Lastly, the data must be reproduced by others to validate the biomarkers, thus the scientific data must be published in well-known, peer-reviewed journals. At least two independent research studies worldwide should confirm the results. Global initiatives, multicenter studies, and consensus protocols of analysis are of crucial importance. In this way, there will be evidence that the novel biomarkers are (or are not) useful in therapeutic studies of AD and other forms of dementia.</p>
      </sec>
    </sec>
    <sec id="sec0095">
      <title>Summary</title>
      <p>At present, only the analysis of A&#x3B2;(1-42), total tau and phospho-tau-181 in CSF allows reliable, sensitive and specific diagnosis of AD, but not of other forms of dementia. Unfortunately, the use of CSF biomarkers is limited because of invasive collection methods. Efforts are underway to discover reliable blood biomarkers. To date, it seems probable that only the combination of several biomarkers derived from blood will be successful to define a patient-specific signature. Early, fast and cheap diagnosis from body fluids using modern, ultrasensitive analytical methods (e.g. microarrays or MS) will become extremely important in the future to differentiate AD from other forms of dementia, and to gauge therapeutic relevance.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frey</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Problems associated with biological markers of Alzheimer's disease</article-title>
          <source>Neurochemical Res.</source>
          <volume>30</volume>
          <year>2005</year>
          <fpage>1501</fpage>
          <lpage>1510</lpage>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henley</surname>
              <given-names>S.M.D.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers for neurodegenerative diseases</article-title>
          <source>Curr. Opin. Neurol.</source>
          <volume>18</volume>
          <year>2005</year>
          <fpage>698</fpage>
          <lpage>705</lpage>
          <pub-id pub-id-type="pmid">16280682</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sprott</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers of aging and disease: introduction and definitions</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>2</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">19651201</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cedazo-Minguez</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers of Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>5</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">19796673</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer's disease biomarker discovery in symtomatic and asymptomatic patients: Experimental approaches and future clinical applications</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>15</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">19796674</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hampel</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives</article-title>
          <source>Nat. Rev. Drug Discov.</source>
          <volume>9</volume>
          <year>2010</year>
          <fpage>560</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="pmid">20592748</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desai</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis and treatment of Alzheimer's disease</article-title>
          <source>Neurology</source>
          <volume>64</volume>
          <year>2005</year>
          <fpage>S34</fpage>
          <lpage>S39</lpage>
          <pub-id pub-id-type="pmid">15994222</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sj&#xF6;gren</surname>
            </name>
          </person-group>
          <article-title>Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers</article-title>
          <source>Clin. Chim. Acta</source>
          <volume>332</volume>
          <year>2003</year>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">12763273</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zetterberg</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid markers for prediction of Alzheimer's disease</article-title>
          <source>Neurosci. Lett.</source>
          <volume>352</volume>
          <year>2003</year>
          <fpage>67</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">14615052</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0050">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blennow</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>CSF biomarkers for mild cognitive impairment</article-title>
          <source>J. Intern. Med.</source>
          <volume>256</volume>
          <year>2004</year>
          <fpage>224</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">15324365</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blennow</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>CSF biomarkers for Alzheimer's disease: use in erarly diagnosis and evaluation of drug treatment</article-title>
          <source>Expert Rev. Mol. Diagn.</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>661</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="pmid">16149870</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0060">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marksteiner</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid(1-42), tau, phospho-tau-181 and total protein</article-title>
          <source>Drugs Today</source>
          <volume>43</volume>
          <year>2007</year>
          <fpage>423</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="pmid">17612711</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blennow</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid and plasma biomarkers in Alzheimer disease</article-title>
          <source>Nat. Rev. Neurol.</source>
          <volume>6</volume>
          <year>2010</year>
          <fpage>131</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="pmid">20157306</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zetterberg</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid &#x3B2; and APP as biomarkers for Alzheimer's disease</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>23</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">19698775</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefani</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>237</volume>
          <year>2005</year>
          <fpage>83</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">15990115</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noguchi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration</article-title>
          <source>Neurol. Sci.</source>
          <volume>237</volume>
          <year>2005</year>
          <fpage>61</fpage>
          <lpage>65</lpage>
        </element-citation>
      </ref>
      <ref id="bib0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sunderland</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid beta-amyloid1-42 and tua in control subjects at risk for Alzheime&#x155;s disease: the effect of APOEe4 allele</article-title>
          <source>Biol. Psychiatry</source>
          <volume>56</volume>
          <year>2004</year>
          <fpage>670</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="pmid">15522251</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0090">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schoonenboom</surname>
              <given-names>N.S.</given-names>
            </name>
          </person-group>
          <article-title>Amyloid beta 38,40 and 42 species in cerebrospinal fluid: More of the same? <italic>Ann</italic></article-title>
          <source>Neurol.</source>
          <volume>58</volume>
          <year>2005</year>
          <fpage>139</fpage>
          <lpage>142</lpage>
        </element-citation>
      </ref>
      <ref id="bib0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Proteomic patterns: their potential for disease diagnosis</article-title>
          <source>Mol. Cell Endocrinol.</source>
          <volume>230</volume>
          <year>2005</year>
          <fpage>95</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="pmid">15664456</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0100">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sj&#xF6;gren</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values</article-title>
          <source>Clin. Chem.</source>
          <volume>47</volume>
          <year>2001</year>
          <fpage>1776</fpage>
          <lpage>1781</lpage>
          <pub-id pub-id-type="pmid">11568086</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0105">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hampel</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Total and phosphorylated tau protein as biological markers of Alzheimer's disease</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>30</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">19853650</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blasko</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias</article-title>
          <source>Dement. Geriatr. Cogn. Disord.</source>
          <volume>21</volume>
          <year>2006</year>
          <fpage>9</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">16244482</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>41</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">19853649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hock</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Increased CSF levels of nerve growth factor in patients with Alzheimer's disease</article-title>
          <source>Neurology</source>
          <volume>54</volume>
          <year>2000</year>
          <fpage>2009</fpage>
          <lpage>2011</lpage>
          <pub-id pub-id-type="pmid">10822447</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0125">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assini</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment</article-title>
          <source>Neurology</source>
          <volume>63</volume>
          <year>2004</year>
          <fpage>828</fpage>
          <lpage>831</lpage>
          <pub-id pub-id-type="pmid">15365131</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borroni</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?</article-title>
          <source>Eur. J. Pharmacol.</source>
          <volume>545</volume>
          <year>2006</year>
          <fpage>73</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">16831417</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0135">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brettschneider</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Decreased serum amyloid beta1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta1-42 peptide</article-title>
          <source>Biol. Psychiatry</source>
          <volume>57</volume>
          <year>2005</year>
          <fpage>813</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="pmid">15820240</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0140">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gustaw-Rothenberg</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Dissociated amyloid-&#x3B2; antibody levels as a serum biomarkerfor the progrssion of Alzheimer&#x2018;s disease: a population-based study</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>47</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">19819324</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0145">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blasko</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy</article-title>
          <source>Neurobiol. Aging</source>
          <volume>26</volume>
          <year>2005</year>
          <fpage>1135</fpage>
          <lpage>1143</lpage>
          <pub-id pub-id-type="pmid">15917096</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Platelet amyloid precursor protein processing: a bio-marker for Alzheimer&#x2018;s disease</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>240</volume>
          <year>2006</year>
          <fpage>53</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">16256140</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0155">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borroni</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Blood cell markers in Alzheimer's disease: amyloid precursor protein form ratio in platelets</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>53</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">19699790</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiala</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>57</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">19699791</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0165">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hye</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease</article-title>
          <source>Neurosci. Lett.</source>
          <volume>373</volume>
          <year>2005</year>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">15555766</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0170">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marksteiner</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Glycogen-synthase kinase-3&#x3B2; is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment</article-title>
          <source>Exp. Gerontol.</source>
          <volume>44</volume>
          <year>2009</year>
          <fpage>370</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">19249342</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0175">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Barry</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C as a peripheral biomarker for Alzheimer's disease</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>64</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">19895879</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0180">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ray</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins</article-title>
          <source>Nat. Med.</source>
          <volume>13</volume>
          <year>2007</year>
          <fpage>1359</fpage>
          <lpage>1362</lpage>
          <pub-id pub-id-type="pmid">17934472</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0185">
        <label>37</label>
        <mixed-citation publication-type="other">Marksteiner, J. <italic>et al.</italic> (2009) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. <italic>Neurobiol. Aging</italic>, <ext-link ext-link-type="doi" xlink:href="10.1016/j.neurobiolaging.2009.03.011">doi:10.1016/j.neurobiolaging.2009.03.011</ext-link></mixed-citation>
      </ref>
      <ref id="bib0190">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soares</surname>
              <given-names>H.D.</given-names>
            </name>
          </person-group>
          <article-title>Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels</article-title>
          <source>Ann. N. Y. Acad. Sci.</source>
          <volume>1180</volume>
          <year>2009</year>
          <fpage>56</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">19906261</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0195">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>G.P.</given-names>
            </name>
          </person-group>
          <article-title>Brain ubiquitin is markedly elevated in Alzheimer disease</article-title>
          <source>Brain Res.</source>
          <volume>566</volume>
          <year>1991</year>
          <fpage>146</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="pmid">1814531</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0200">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ponnappan</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitin&#x2013;proteasome pathway is compromised in CD45RO+ and CD45RA+ T lymphocyte subsets during aging</article-title>
          <source>Exp. Gerontol.</source>
          <volume>37</volume>
          <year>2002</year>
          <fpage>359</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">11772523</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0205">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kudo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels</article-title>
          <source>Brain Res.</source>
          <volume>639</volume>
          <year>1994</year>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">8180825</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0210">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ullrich</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients</article-title>
          <source>Curr. Alzheimer Res.</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>549</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">20455864</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0215">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baird</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Telomeres</article-title>
          <source>Exp. Gerontol.</source>
          <volume>41</volume>
          <year>2006</year>
          <fpage>1223</fpage>
          <lpage>1227</lpage>
          <pub-id pub-id-type="pmid">17084054</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0220">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lukens</surname>
              <given-names>J.N.</given-names>
            </name>
          </person-group>
          <article-title>Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease</article-title>
          <source>Alzheimer's Dement</source>
          <volume>5</volume>
          <year>2009</year>
          <fpage>463</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="pmid">19896585</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0225">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panossian</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Telomere shortening in T cells correlates with Alzheimer's disease status</article-title>
          <source>Neurobiol. Aging</source>
          <volume>24</volume>
          <year>2003</year>
          <fpage>77</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">12493553</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0230">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Zglinicki</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?</article-title>
          <source>Lab. Invest.</source>
          <volume>80</volume>
          <year>2000</year>
          <fpage>1739</fpage>
          <lpage>1747</lpage>
          <pub-id pub-id-type="pmid">11092534</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0235">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lanni</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Unfolded p53: a potential biomarker for Alzheimer's disease</article-title>
          <source>J. Alzheimer's Dis.</source>
          <volume>12</volume>
          <year>2007</year>
          <fpage>93</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="pmid">17851197</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0240">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergman</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli?</article-title>
          <source>Alzheimer Dis. Assoc. Disord.</source>
          <volume>16</volume>
          <year>2002</year>
          <fpage>156</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">12218646</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0245">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leuner</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer disease</article-title>
          <source>J. Neural Transm.</source>
          <volume>72</volume>
          <year>2007</year>
          <fpage>207</fpage>
          <lpage>215</lpage>
        </element-citation>
      </ref>
      <ref id="bib0250">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ankarcrona</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers for apoptosis in Alzheimer disease</article-title>
          <source>Int. J. Geriatr. Psychiatry</source>
          <volume>20</volume>
          <year>2005</year>
          <fpage>101</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="pmid">15660410</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0255">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindowski</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis of CD4+ T and natural killer cells in Alzheimer's disease</article-title>
          <source>Pharmacopsychiatry</source>
          <volume>39</volume>
          <year>2006</year>
          <fpage>220</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="pmid">17124644</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0260">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tacconi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease</article-title>
          <source>Exp. Neurol.</source>
          <volume>190</volume>
          <year>2004</year>
          <fpage>254</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="pmid">15473998</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0265">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ewers</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Blood-based biomarkers of microvascular pathology in Alzheimer's disease</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>75</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">19782124</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0270">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuo</surname>
              <given-names>H.K.</given-names>
            </name>
          </person-group>
          <article-title>Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis</article-title>
          <source>Lancet Neurol.</source>
          <volume>4</volume>
          <year>2005</year>
          <fpage>371</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">15907742</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0275">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease</article-title>
          <source>Arch Neurol.</source>
          <volume>55</volume>
          <year>1998</year>
          <fpage>1449</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="pmid">9823829</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0280">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hochstrasser</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Soluble cell adhesion molecules in monocytes of Alzheimer&#x2032;s disease and mild cognitive impairment</article-title>
          <source>Exp. Gerontol.</source>
          <volume>45</volume>
          <year>2010</year>
          <fpage>70</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="pmid">19836440</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0285">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thambisetty</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Blood-based biomarkers of Alzheimer's disease: challenging but feasible</article-title>
          <source>Biomark. Med.</source>
          <volume>4</volume>
          <year>2010</year>
          <fpage>65</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">20387303</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0290">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teunissen</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking</article-title>
          <source>Neurology</source>
          <volume>73</volume>
          <year>2009</year>
          <fpage>1914</fpage>
          <lpage>1922</lpage>
          <pub-id pub-id-type="pmid">19949037</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0295">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verwey</surname>
              <given-names>N.A.</given-names>
            </name>
          </person-group>
          <article-title>A worldwide multicentre comparison of assay for cerebrospinal fluid biomarkers in Alzheimer's disease</article-title>
          <source>Ann. Clin. Biochem.</source>
          <volume>46</volume>
          <year>2009</year>
          <fpage>235</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">19342441</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0300">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewczuk</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study</article-title>
          <source>Neurobiol. Aging</source>
          <volume>29</volume>
          <year>2008</year>
          <fpage>812</fpage>
          <lpage>818</lpage>
          <pub-id pub-id-type="pmid">17239996</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0305">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Snowdown</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Healthy aging and dementia: findings from the Nun Study</article-title>
          <source>Ann. Intern. Med.</source>
          <volume>139</volume>
          <year>2003</year>
          <fpage>450</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="pmid">12965975</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0310">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gr&#xFC;nblatt</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Gene expression as peripheral biomarkers for sporadic Alzheime&#x155;s disease</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>16</volume>
          <year>2009</year>
          <fpage>627</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">19276557</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0315">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdi</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>9</volume>
          <year>2006</year>
          <fpage>293</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="pmid">16914840</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0320">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singer</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease</article-title>
          <source>Anal. Bioanal. Chem.</source>
          <volume>395</volume>
          <year>2009</year>
          <fpage>2263</fpage>
          <lpage>2267</lpage>
          <pub-id pub-id-type="pmid">19821112</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0325">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marvin</surname>
              <given-names>L.F.</given-names>
            </name>
          </person-group>
          <article-title>Matrix-assisted laser desorption/ionization time-of-flight mass spectometry in clinical chemistry</article-title>
          <source>Clin. Chim. Acta</source>
          <volume>337</volume>
          <year>2003</year>
          <fpage>11</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">14568176</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0330">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oe</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheime&#x155;s disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry</article-title>
          <source>Rapid Comm. Mass Spectrom.</source>
          <volume>20</volume>
          <year>2006</year>
          <fpage>3723</fpage>
          <lpage>3735</lpage>
        </element-citation>
      </ref>
      <ref id="bib0335">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hutchinson</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Imaging and spatial distribution of beta-amyloid peptide and metal ions in Alzheimer's plaques by laser ablation-inductively coupled plasma-mass spectrometry</article-title>
          <source>Anal. Biochem.</source>
          <volume>346</volume>
          <year>2005</year>
          <fpage>225</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="pmid">16214103</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0340">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wittke</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches</article-title>
          <source>Electrophoresis</source>
          <volume>26</volume>
          <year>2005</year>
          <fpage>1476</fpage>
          <lpage>1487</lpage>
          <pub-id pub-id-type="pmid">15765478</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0345">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kellner</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden</article-title>
          <source>Ann. Neurol.</source>
          <volume>65</volume>
          <year>2009</year>
          <fpage>24</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">19194878</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0350">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cogswell</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways</article-title>
          <source>J. Alzheimers Dis.</source>
          <volume>14</volume>
          <year>2008</year>
          <fpage>27</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">18525125</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0355">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginsberg</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Single cell gene expression profiling in Alzheimer's disease</article-title>
          <source>NeuroRx</source>
          <volume>3</volume>
          <year>2006</year>
          <fpage>302</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="pmid">16815214</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0360">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schipper</surname>
              <given-names>H.M.</given-names>
            </name>
          </person-group>
          <article-title>MicroRNA expression in Alzheimer blood mononuclear cells</article-title>
          <source>Gene Regul. Syst. Bio.</source>
          <volume>1</volume>
          <year>2007</year>
          <fpage>263</fpage>
          <lpage>274</lpage>
        </element-citation>
      </ref>
      <ref id="bib0365">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maes</surname>
              <given-names>O.C.</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional profiling of Alzheimer blood mononuclear cells by microarray</article-title>
          <source>Neurobiol. Aging</source>
          <volume>28</volume>
          <year>2007</year>
          <fpage>1795</fpage>
          <lpage>1809</lpage>
          <pub-id pub-id-type="pmid">16979800</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0370">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <article-title>MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform</article-title>
          <source>Rapid Commun. Mass Spectrom.</source>
          <volume>24</volume>
          <year>2010</year>
          <fpage>403</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="pmid">20069694</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0375">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frankfort</surname>
              <given-names>S.V.</given-names>
            </name>
          </person-group>
          <article-title>Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS)</article-title>
          <source>Curr. Clin. Pharmacol.</source>
          <volume>3</volume>
          <year>2008</year>
          <fpage>144</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">18781900</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0380">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simonsen</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease</article-title>
          <source>Neurobiol. Aging</source>
          <volume>29</volume>
          <year>2007</year>
          <fpage>961</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="pmid">17321007</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0385">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maddalena</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology</article-title>
          <source>Neurodegener. Dis.</source>
          <volume>1</volume>
          <year>2004</year>
          <fpage>231</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">16908995</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>The work on biomarker identification was supported by the Austrian Science Funds (Translational Project L429-B05).</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig0005">
      <label>Figure 1</label>
      <caption>
        <p>The principal steps necessary for AD biomarker discovery (left flowchart) and for routine analysis of CSF samples (right flowchart). Similar steps are shown in red boxes. Only a good clinical diagnosis is the basis for statistical analysis of biomarker discovery. To date, laboratory diagnosis only supports the clinical diagnosis, which cannot be regarded as a stand-alone diagnostic tool.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <table-wrap id="tbl0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Internationally established biomarkers in CSF used to diagnose AD<xref rid="tblfn0005" ref-type="table-fn">a</xref></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Biomarker</th>
            <th align="left">Controls (pg/ml)</th>
            <th align="left">AD (pg/ml)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">A&#x3B2;(1&#x2013;42)</td>
            <td align="left">794&#xB1;20</td>
            <td align="left">&lt;500<xref rid="tblfn0015" ref-type="table-fn">*</xref></td>
          </tr>
          <tr>
            <td align="left">Total tau</td>
            <td align="left">136&#xB1;89 (21&#x2013;50 years)</td>
            <td align="left">
              <xref rid="tblfn0010" ref-type="table-fn">b</xref>
            </td>
          </tr>
          <tr>
            <td/>
            <td align="left">243&#xB1;127 (51&#x2013;70 years)</td>
            <td align="left">&gt;450</td>
          </tr>
          <tr>
            <td/>
            <td align="left">341&#xB1;171 (&gt;71 years)</td>
            <td align="left">&gt;600<xref rid="tblfn0015" ref-type="table-fn">*</xref></td>
          </tr>
          <tr>
            <td align="left">Phospho-tau-181</td>
            <td align="left">23&#xB1;2</td>
            <td align="left">&gt;60<xref rid="tblfn0015" ref-type="table-fn">*</xref></td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0005">
          <label>a</label>
          <p>Data obtained using the Innogenetics single 96-well ELISA kits.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0010">
          <label>b</label>
          <p>This is not relevant for sporadic AD, because it is only for patients &gt;60 years of age.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0015">
          <label>*</label>
          <p><italic>P</italic>&lt;0.001</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0010" position="float">
      <label>Table 2</label>
      <caption>
        <p>Changes in the levels of established CSF biomarkers in different central nervous system diseases</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Disease</th>
            <th align="left">A&#x3B2;(1&#x2013;42)</th>
            <th align="left">Total tau</th>
            <th align="left">Phospho-tau-181</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Acute stroke</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2191;(&#x2191;)</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">Alcohol dementia</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">AD</td>
            <td align="left">&#x2193;</td>
            <td align="left">&#x2191;</td>
            <td align="left">&#x2191;</td>
          </tr>
          <tr>
            <td align="left">CJD</td>
            <td align="left">&#x2193;&#x2193;</td>
            <td align="left">&#x2191;&#x2191;&#x2191;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">Depression</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">FTLD</td>
            <td align="left">&#x2193;</td>
            <td align="left">&#x2191;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">LBD</td>
            <td align="left">&#x2193;</td>
            <td align="left">&#x2191;</td>
            <td align="left">&#x2191;</td>
          </tr>
          <tr>
            <td align="left">Neuroinflammation</td>
            <td align="left">&#x2193;</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">Normal aging</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">Parkinson's disease</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
            <td align="left">&#x2013;</td>
          </tr>
          <tr>
            <td align="left">VaD</td>
            <td align="left">&#x2193;(&#x2193;)</td>
            <td align="left">&#x2191;</td>
            <td align="left">&#x2013;</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>a</sup>Modified according to Ref. <xref rid="bib0070" ref-type="bibr">[14]</xref>: (&#x2013;), no change; (&#x2193;), decrease; (&#x2191;), increase.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0015" position="float">
      <label>Table 3</label>
      <caption>
        <p>Selected examples of methods to discover biomarkers for AD diagnosis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Analytical method</th>
            <th align="left">Description</th>
            <th align="left">Biomarker</th>
            <th align="left">Refs.</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">ELISA</td>
            <td align="left">Single 96-well assay</td>
            <td align="left">A&#x3B2;42, total tau, phospho-tau-181 (single)</td>
            <td align="left">
              <xref rid="bib0045 bib0050 bib0060 bib0110" ref-type="bibr">[9,10,12,22]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Multiplex Searchlight ELISAs (Aushon)</td>
            <td align="left">16 (chemiluminescence) or 24 (infrared) markers per single well in 96-well</td>
            <td align="left">16 signaling proteins</td>
            <td align="left">
              <xref rid="bib0185" ref-type="bibr">[37]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Filter-based array sandwich ELISA</td>
            <td align="left">&#x2018;Capture&#x2019; antibody is on a filter; requires detection antibody after antigen capture</td>
            <td align="left">18 signaling proteins</td>
            <td align="left">
              <xref rid="bib0180" ref-type="bibr">[36]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">INNO-BIA AlzBio3 Luminex-based technology (Innogenetics)</td>
            <td align="left">Liquid bead arrays; xMAP</td>
            <td align="left">A&#x3B2;42, total tau, phospho- tau-181 (multiplex)</td>
            <td align="left">
              <xref rid="bib0300" ref-type="bibr">[60]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Tissue array</td>
            <td align="left">Antigen-spotted microarray to detect auto-antibodies; consists of paraffin blocks with 1,000 separated tissues for multiplexed histological analysis</td>
            <td align="left">2,325 tissue specimens</td>
            <td align="left">
              <xref rid="bib0345" ref-type="bibr">[69]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Quantitative real-time RT-PCR</td>
            <td align="left">Amplification of DNA alone or coupled to immunoassays (immuno-PCR)</td>
            <td align="left">33 genes; multiple phosporylated tau-epitopes</td>
            <td align="left">
              <xref rid="bib0310 bib0320" ref-type="bibr">[62,64]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Liquid chromatography/electrospray ionisation MS</td>
            <td/>
            <td align="left">A&#x3B2;40, A&#x3B2;42</td>
            <td align="left">
              <xref rid="bib0330" ref-type="bibr">[66]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Capillary electrophoresis/MS</td>
            <td align="left">Rapid, 60-min analysis</td>
            <td align="left">1000 polypeptides</td>
            <td align="left">
              <xref rid="bib0340" ref-type="bibr">[68]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Ultrasensitive laser ablation inductively coupled plasma/MS</td>
            <td/>
            <td align="left">Trace elements and metal ions</td>
            <td align="left">
              <xref rid="bib0335" ref-type="bibr">[67]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Multiplex iTRAQ</td>
            <td align="left">Isobaric tagging for relative and absolute protein quantification with multi-dimensional chromatography and tandem MS</td>
            <td align="left">1,500 CSF proteins</td>
            <td align="left">
              <xref rid="bib0315" ref-type="bibr">[63]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">Surface-enhanced laser desorption/ionization (SELDI)- or matrix-assisted laser desorption/ionization (MALDI)-MS</td>
            <td align="left">Time-of-flight (TOF) MS</td>
            <td align="left">Several A&#x3B2; species: A&#x3B2;37, A&#x3B2;36, A&#x3B2;38, A&#x3B2;40; several other biomarkers</td>
            <td align="left">
              <xref rid="bib0095 bib0325 bib0370 bib0375 bib0380 bib0385" ref-type="bibr">[19,65,74&#x2013;77]</xref>
            </td>
          </tr>
          <tr>
            <td align="left">DNA/RNA chips, BioChips, GeneChips</td>
            <td align="left">Microspots on a matrix with a single, defined species of nucleic acids</td>
            <td align="left">Several thousand genes</td>
            <td align="left">
              <xref rid="bib0350 bib0355 bib0360 bib0365" ref-type="bibr">[70&#x2013;73]</xref>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <boxed-text id="tb0005">
      <label>Box 1</label>
      <caption>
        <title>Criteria for establishing a good biomarker for the diagnosis of dementia</title>
      </caption>
      <p>
        <list list-type="simple">
          <list-item>
            <label>&#x2022;</label>
            <p>Reflect physiological aging processes</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Reflect basic pathophysiological processes of the brain</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>React upon pharmacological intervention</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Display high sensitivity</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Display high specificity for the disease as compared with related disorders</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Allow measurements repeatedly over time</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Allow reproducibility in laboratories worldwide</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Should be measurable in noninvasive, easy-to-perform tests</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Should not cause harm to the individuals being assessed</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Tests should be inexpensive and rapid</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Samples should be stable to allow easy and cheap transport</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Easy collection of fluids not only in hospitals</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Changes should be at least twofold to allow differentiation of controls</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Define good cut-off values to distinguish diseases</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Data published in peer-reviewed journals</p>
          </list-item>
          <list-item>
            <label>&#x2022;</label>
            <p>Data reproduced by at least two independent researchers</p>
          </list-item>
        </list>
      </p>
    </boxed-text>
    <boxed-text id="tb0010">
      <label>Box 2</label>
      <caption>
        <title>Tissue and liquids to screen for biomarkers: advantages and disadvantages</title>
      </caption>
      <p>Biomarkers can be discoverd from different human tissues or liquids. The analysis of postmortem brain tissue is necessary to verify AD by immunohistochemical analysis of plaques (A&#x3B2;) and tangles (tau). Postmortem analysis or, alternatively, brain biopsies might also allow screening for general pathological changes in the AD brain, but are not useful for routine biomarker analysis. CSF is a very useful fluid for AD diagnosis, because it reflects metabolic processes in the brain owing to direct contact between the brain and CSF. Its diagnostic use is only limited because of invasive collection by lumbar puncture.</p>
      <p>Plasma/serum measurements are the gold standard in clinics, because they are minimally invasive, as compared with CSF, and therefore easily collected and processed. For AD biomarker discovery, the use of plasma is still limited, because changes are very small and heterogeneous and plasma/serum data reflect a broad spectrum of changes; not all necessarily related to AD. A major advantage of blood samples is that patients can be followed up and screened over several years. The analysis of blood cells (e.g. peripheral blood mononuclear cells, lymphocytes, monocytes or platelets) might be more restricted to specific AD-related pathologies. The disadvantage is the more complex and time-consuming processing of blood cells, especially when culturing blood cells under sterile conditions. The collection of other fluids (e.g. saliva, urine, fibroblasts, or eye secretions) is fast, cheap and noninvasive; however, the use of these fluids requires very sensitive methods to detect low-level proteins and the correlation to AD pathologies is unclear.</p>
    </boxed-text>
  </floats-group>
</article>
